Claas F H, Abbott P A, Witvliet M D, D'Amaro J, Barnes P M, Krupp P
Department of Immunohaematology and Blood Bank, University Hospital, Leiden, The Netherlands.
Drug Saf. 1992;7 Suppl 1:3-6. doi: 10.2165/00002018-199200071-00004.
The clinical use of clozapine in psychiatry is restricted by the associated risk of agranulocytosis. This risk is significantly higher than that associated with conventional antipsychotic medications. In order to identify a possible parameter to detect susceptible individuals before treatment, 103 patients with a history of clozapine-induced granulocytopenia or agranulocytosis and 95 matched control patients were typed for human leucocyte antigen (HLA)-A, -B, -C, -DR, -DQ and for a number of neutrophil-specific alloantigens. No significant association between certain HLA alleles or neutrophil antigens and susceptibility to clozapine-induced granulocytopenia or agranulocytosis was observed.
氯氮平在精神病学中的临床应用因粒细胞缺乏症相关风险而受到限制。这种风险显著高于传统抗精神病药物相关的风险。为了确定一个在治疗前检测易感个体的可能参数，对103例有氯氮平诱导的粒细胞减少症或粒细胞缺乏症病史的患者和95例匹配的对照患者进行了人类白细胞抗原（HLA）-A、-B、-C、-DR、-DQ以及一些中性粒细胞特异性同种抗原的分型。未观察到某些HLA等位基因或中性粒细胞抗原与氯氮平诱导的粒细胞减少症或粒细胞缺乏症易感性之间存在显著关联。
